Sartorius AG banner

Sartorius AG
OTC:SARTF

Watchlist Manager
Sartorius AG Logo
Sartorius AG
OTC:SARTF
Watchlist
Price: 226.33 USD Market Closed
Market Cap: $15.6B

Net Margin

3.8%
Current
Declining
by 2%
vs 3-y average of 5.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3.8%
=
Net Income
€133.7m
/
Revenue
€3.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3.8%
=
Net Income
$133.7m
/
Revenue
€3.5B

Peer Comparison

Country Company Market Cap Net
Margin
DE
Sartorius AG
XETRA:SRT
12.9B EUR
Loading...
US
Abbott Laboratories
NYSE:ABT
189.6B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
171B USD
Loading...
US
Stryker Corp
NYSE:SYK
138.8B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
132.5B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
115.7B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
46.4B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
51.8B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
45.4B USD
Loading...
US
Resmed Inc
NYSE:RMD
39B USD
Loading...

Market Distribution

In line with most companies in Germany
Percentile
60th
Based on 3 835 companies
60th percentile
3.8%
Low
-222 027.4% — -2%
Typical Range
-2% — 6%
High
6% — 85 055.6%
Distribution Statistics
Germany
Min -222 027.4%
30th Percentile -2%
Median 2.2%
70th Percentile 6%
Max 85 055.6%

Sartorius AG
Glance View

Market Cap
15.6B USD
Industry
Health Care

Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.

SARTF Intrinsic Value
229.92 USD
Undervaluation 2%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
3.8%
=
Net Income
€133.7m
/
Revenue
€3.5B
What is Sartorius AG's current Net Margin?

The current Net Margin for Sartorius AG is 3.8%, which is below its 3-year median of 5.8%.

How has Net Margin changed over time?

Over the last 3 years, Sartorius AG’s Net Margin has decreased from 13.6% to 3.8%. During this period, it reached a low of 2.3% on Jun 30, 2024 and a high of 16.2% on Dec 31, 2022.

Back to Top